EMA — authorised 18 January 2017
- Marketing authorisation holder: Merck Sharp & Dohme B.V.
- Status: approved
🇪🇺 Zinplava in European Union
EMA authorised Zinplava on 18 January 2017
Marketing authorisations
EMA — authorised 18 January 2017
- Application: EMEA/H/C/004136
- Marketing authorisation holder: Merck Sharp & Dohme B.V.
- Local brand name: Zinplava
- Indication: Zinplava is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
- Status: approved
Zinplava in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in European Union
Frequently asked questions
Is Zinplava approved in European Union?
Yes. EMA authorised it on 18 January 2017; EMA authorised it on 18 January 2017.
Who is the marketing authorisation holder for Zinplava in European Union?
Merck Sharp & Dohme B.V. holds the EU marketing authorisation.